Latest period
$10.00K
YoY change
—
5Y CAGR
-100.0%
Peak year (2021)
$93.00K
Cumulative CapEx
$196.00K
CapEx history chart for Spruce Biosciences (SPRB) from 2018 to 2025
Latest: $0.00
CapEx growth chart for Spruce Biosciences (SPRB) from 2018 to 2025
Latest: -100.0%
CapEx history table for Spruce Biosciences (SPRB) from 2018 to 2025
| 2025 | $0.00 | — | $0.00 | ||
| 2024 | $0.00 | -100.0% | −$7.00K | ||
| 2023 | $7.00K | -12.5% | −$1.00K | ||
| 2022 | $8.00K | -91.4% | −$85.00K | ||
| 2021 | $93.00K | +25.7% | +$19.00K | ||
| 2020 | $74.00K | +1750.0% | +$70.00K | ||
| 2019 | $4.00K | — | +$4.00K | ||
| 2018 | $0.00 | — | — |
- 2025$0.00—
- 2024$0.00-100.0%
- 2023$7.00K-12.5%
- 2022$8.00K-91.4%
- 2021$93.00K+25.7%
- 2020$74.00K+1750.0%
- 2019$4.00K—
- 2018$0.00—
CapEx values are taken from Spruce Biosciences's reported cash flow statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About CapEx at Spruce Biosciences (SPRB)
According to Spruce Biosciences's latest reported financial statements, the company's current CapEx (TTM) is $10.00K. Capital expenditures (CapEx) are cash outlays for property, plant, and equipment and other long-lived productive assets — reported on the cash flow statement under investing activities. CapEx funds future capacity (factories, data centers, software, machinery), so rising spend can signal investment in growth, while heavy CapEx reduces free cash flow available to shareholders. We display CapEx as a positive amount (the absolute cash outflow); compare with revenue to gauge capital intensity and with total assets for the asset-base context.
Headline TTM above sums the four reported quarters through (reported ). Chart and table below cover the full reported history back to .
Spruce Biosciences (SPRB) most recent annual CapEx stands at $0.00 (2025).
Through 2020–2025 (5 years), Spruce Biosciences CapEx delivered a -100.0% annualised rate; with a net decline across the window.
Spruce Biosciences CapEx plunged from $93.00K in 2021 to $0.00 in 2025, a 100.0% drawdown.
$93.00K stands as the all-time-high annual CapEx, posted in 2021, against a low of $0.00 during 2018.
Spruce Biosciences Capital Expenditures by Year
Spruce Biosciences Capital Expenditures 2025: $0.00
Spruce Biosciences CapEx in 2025 was $0.00.
Spruce Biosciences Capital Expenditures 2024: $0.00
Spruce Biosciences CapEx in 2024 was $0.00, plunged 100.0% below 2023.
Spruce Biosciences Capital Expenditures 2023: $7.00K
2023's CapEx for Spruce Biosciences came in at $7.00K, declined 12.5% below 2022.
Spruce Biosciences Capital Expenditures 2022: $8.00K
Spruce Biosciences posted CapEx of $8.00K in 2022, plunged 91.4% below 2021.
Spruce Biosciences Capital Expenditures 2021: $93.00K
Spruce Biosciences CapEx in 2021 was $93.00K.
See more financial history for Spruce Biosciences (SPRB).
Sector peers by CapEx
Healthcare peers of Spruce Biosciences (SPRB), ranked by their latest CapEx
| $14.05B | |
| $7.84B | |
| $4.83B | |
| $4.11B | |
| $3.62B | |
| $2.81B | |
| $1.86B | |
| $1.21B |
- $14.05B
- $7.84B
- $4.83B
- $4.11B
- $3.62B
- $2.81B
- $1.86B
- $1.21B
Frequently asked questions
Spruce Biosciences (SPRB) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation